Fig. 6: The role of RNF19A in response to cancer therapy.

a–b Sensitivity of control and RNF19A overexpression MDA-MB-231 (a) and HCC1806 cells to Olaparib was assessed by colony formation assay. c–e MDA-MB-231 cells stably expressing Vec or Flag-RNF19A were subcutaneously injected into nude mice. Tumor weight (c) and volume (d) were measured as indicated. Tumor images were acquired as shown in e. f–h Kaplan–Meier estimates of overall survival of breast cancer patients with different expression levels of BARD1 and RNF19A. The log-rank test was used to compare the survival curves between groups. i Nuclear (Nuc) cytoplasmic (Cyto) BARD1 staining was evaluated by the German semi-quantitative scoring system according to the staining intensity and the proportion was compared between tumor (n = 140, mini-0.25, max-2, centre-1, lower quartile-0.8, upper quartile-1) and adjacent tissues (n = 46, mini-1, max-2, centre-1, lower quartile-1, upper quartile-1.33). j Proportion of nuclear (Nuc)/cytoplasm (Cyto) staining of BARD1 was compared between RNF19A high (n = 79, mini-0.25, max-1, centre-0.8, lower quartile-0.75, upper quartile-1) and low (n = 61, mini-1, max-2, centre-1, lower quartile-1, upper quartile-1.33) expression subgroups. k Representative images of IHC analysis of RNF19A and BARD1 in the serial sections of tumor tissues. Scale bars, 100 μM. Values are means ± s.d. of three (a and b) or five (c and d) independent experiments. p values are determined by unpaired two-sided t test in a–d and i–j. Source data are provided as a Source Data file.